PDS Biotechnology Corporation (PDSB): Price and Financial Metrics
GET POWR RATINGS... FREE!
PDSB Stock Price Chart Interactive Chart >
PDSB Price/Volume Stats
| Current price | $8.33 | 52-week high | $13.65 |
| Prev. close | $8.42 | 52-week low | $2.89 |
| Day low | $8.22 | Volume | 713,565 |
| Day high | $8.68 | Avg. volume | 719,198 |
| 50-day MA | $9.66 | Dividend yield | N/A |
| 200-day MA | $5.78 | Market Cap | 237.06M |
PDS Biotechnology Corporation (PDSB) Company Bio
PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc. Following the merger, Edge will operate as “PDS Biotechnology Corporation” and the stock will trade on the Nasdaq Capital Market beginning on March 18, 2019 under the ticker symbol \
Latest PDSB News From Around the Web
Below are the latest news stories about PDS BIOTECHNOLOGY CORP that investors may wish to consider to help them evaluate PDSB as an investment opportunity.
PDS Biotechnology (PDSB) Investor Presentation - Slideshow (NASDAQ:PDSB)The following slide deck was published by PDS Biotechnology Corporation in conjunction with this event. |
PDS Biotechnology Corporation (NASDAQ: PDSB) Fell -31.5% From Highs, What Does The Future Hold?PDS Biotechnology Corporation (NASDAQ:PDSB)’s traded shares stood at 0.76 million during the last session, with the company’s beta value hitting 2.41. At the close of trading, the stock’s price was $10.38, to imply an increase of 1.07% or $0.11 in intraday trading. The PDSB share’s 52-week high remains $13.65, putting it -31.5% down since that … PDS Biotechnology Corporation (NASDAQ: PDSB) Fell -31.5% From Highs, What Does The Future Hold? Read More » |
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology ConferenceFLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference being held virtually on January 18-19, 2023. B. Riley Securities 3rd Annual Oncology ConferenceFireside Chat: Thursday, January 19, 2023Ti |
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer TreatmentPDS Biotechnology Corporation (NASDAQ: PDSB ) announced an exclusive global license agreement with Merck KGaA (OTC: MKGAF ) (OTC: MKKGY ) for the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. Under the terms of the agreement, PDS Biotech will receive from Merck KGaA an … Full story available on Benzinga.com |
PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On TuesdayU.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session. SoundHound AI, Inc. (NASDAQ: SOUN ) shares dipped 19% to $1.43 after climbing around 72% on Friday. Inter & Co, Inc. (NASDAQ: INTR ) dropped 17.7% to $1.9501. Mammoth Energy Services, Inc. (NASDAQ: TUSK ) fell 17.3% to $7.15. Valens Semiconductor Ltd. (NYSE: VLN ) declined 17% to $4.4800. PDS Biotechnology Corporation (NASDAQ: PDSB ) fell 15.3% to $11.18. PDS Biotech announced exclusive global license agreement for investigational IL-12 tumor-targeted cytokine … Full story available on Benzinga.com |
PDSB Price Returns
| 1-mo | -36.89% |
| 3-mo | 64.30% |
| 6-mo | 62.06% |
| 1-year | 39.77% |
| 3-year | 237.25% |
| 5-year | -96.85% |
| YTD | -36.89% |
| 2022 | 62.96% |
| 2021 | 278.50% |
| 2020 | -19.25% |
| 2019 | -58.72% |
| 2018 | -96.57% |
Loading social stream, please wait...